Cargando…
Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis
Autores principales: | Pallais, Jean Pierre, Kotz, Catherine M., Stanojlovic, Milos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034266/ https://www.ncbi.nlm.nih.gov/pubmed/31823881 http://dx.doi.org/10.4103/1673-5374.270310 |
Ejemplares similares
-
Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson’s Disease
por: Stanojlovic, Milos, et al.
Publicado: (2019) -
Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson’s Disease
por: Stanojlovic, Milos, et al.
Publicado: (2021) -
Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson’s disease
por: Stanojlovic, Milos, et al.
Publicado: (2019) -
Neuronal and endothelial transglutaminase-2 expression in experimental autoimmune encephalomyelitis and multiple sclerosis
por: Pearse, Damien D., et al.
Publicado: (2021) -
Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis
por: Lin, Wensheng
Publicado: (2017)